Mixed connective tissue disease (MCTD) is an autoimmune condition with overlapping features of lupus, systemic sclerosis, and polymyositis. Maternal–fetal outcomes specific to MCTD remain poorly characterized; a scoping review was conducted.
Methods
Five databases were queried. Extracted data included demographics, antibody profiles, symptoms, treatments, and maternal–fetal outcomes. Descriptive analysis was performed.
Results
Of 269 articles, 33 met inclusion criteria, including 375 pregnancies. Common symptoms and disease manifestations included Raynaud's phenomenon, arthralgias, and sclerodactyly. Treatments included hydroxychloroquine, azathioprine, and corticosteroids. Maternal complications included interstitial lung disease (21.4%), gestational hypertension (HTN) (15.6%), chronic HTN (7.0%), pulmonary HTN (9.8%), eclampsia (1.4%), miscarriage (20.3%), preterm birth (19.6%), and stillbirth (8.1%). Fetal complications included chondrodysplasia punctata (18.2%), demise (6.5%), neonatal lupus erythematosus (3.3%), and congenital heart block (1.0%).
Conclusion
While most MCTD pregnancies resulted in live birth, they carry elevated maternal and perinatal risks that warrant heightened surveillance and tailored management.
CelikbilekMElsurerRAfsarB, et al.Mixed connective tissue disease: a case with scleroderma renal crisis following abortion. Clin Rheumatol2007; 26: 1545–1547.
3.
ChungLFlycktRLColónI, et al.Outcome of pregnancies complicated by systemic sclerosis and mixed connective tissue disease. Lupus2006; 15: 595–599.
4.
UngprasertPCrowsonCSChowdharyVR, et al.Epidemiology of mixed connective tissue disease 1985-2014: a population based study. Arthritis Care Res2016; 68: 1843–1848.
5.
SinghMWambuaSLeeSI, et al.Autoimmune diseases and adverse pregnancy outcomes: an umbrella review. Lancet Lond Engl2023; 402: S84.
6.
BarilaroGCastellanosAGomez-FerreiraI, et al.Systemic sclerosis and pregnancy outcomes: a retrospective study from a single center. Arthritis Res Ther2022; 24: 91.
7.
TanYYangSLiuQ, et al.Pregnancy-related complications in systemic lupus erythematosus. J Autoimmun2022; 132: 102864.
8.
TangKZhouJLanY, et al.Pregnancy in adult-onset dermatomyositis/polymyositis: a systematic review. Am J Reprod Immunol N Y N 19892022; 88: e13603.
9.
TuccinardiACzuzoj-ShulmanNAbenhaimHA. Maternal and neonatal outcomes among pregnant women with inflammatory myopathies. J Perinat Med2022; 50: 587–594.
10.
SammaritanoLRBermasBLChakravartyEE, et al.2020 American College of Rheumatology Guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol2020; 72: 529–556.
11.
Society for Maternal-Fetal Medicine (SMFM), SilverRCraigoS, et al.Society for Maternal-Fetal Medicine Consult Series #64: systemic lupus erythematosus in pregnancy. Am J Obstet Gynecol2023; 228: B41–B60.
12.
KitridouRC. Pregnancy in mixed connective tissue disease. Rheum Dis Clin North Am2005; 31: 497–508.
13.
TardifMLMahoneM. Mixed connective tissue disease in pregnancy: a case series and systematic literature review. Obstet Med2019; 12: 31–37.
14.
IndrajitINarayanS. Chondrodysplasia punctata. Med J Armed Forces India1999; 55: 345–347.
15.
ArkseyHO’MalleyL. Scoping studies: towards a methodological framework. Int J Soc Res Methodol2005; 8: 19–32.
16.
OuzzaniMHammadyHFedorowiczZ, et al.Rayyan—a web and mobile app for systematic reviews. Syst Rev2016; 5: 210.
17.
MoherDLiberatiATetzlaffJ, et al.the PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med2009; 151: 264–269.
18.
American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 200: early pregnancy loss. Obstet Gynecol2018; 132: e197–e207.
BelloNAZhouHCheethamTC, et al.Prevalence of hypertension among pregnant women when using the 2017 American College of Cardiology/American Heart Association Blood Pressure Guidelines and Association With Maternal and Fetal Outcomes. JAMA Netw Open2021; 4: e213808.
Fishel BartalMSibaiBM. Eclampsia in the 21st century. Am J Obstet Gynecol2022; 226: S1237–S1253.
25.
MaherTM. Interstitial lung disease: a review. JAMA2024; 331: 1655–1665.
26.
MaligireddyAJabriAZghouziM, et al.Maternal and fetal outcomes in pulmonary hypertension during pregnancy: a contemporary nationwide analysis. Am J Cardiol2024; 221: 113–119.
27.
HuangJManYShiZ, et al.Global, regional, and national burden of maternal disorders, 1990-2021: a systematic analysis from the global burden of disease study 2021. BMC Public Health2025; 25: 2576.
WangHLiNChiveseT, et al.IDF diabetes atlas: estimation of global and regional gestational diabetes mellitus prevalence for 2021 by International Association of Diabetes in Pregnancy Study Group’s criteria. Diabetes Res Clin Pract2022; 183: 109050.
30.
Cortés-HernándezJOrdi-RosJParedesF, et al.Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies. Rheumatology2002; 41: 643–650.
31.
ClarkKEEtomiOOngVH. Systemic sclerosis in pregnancy. Obstet Med2020; 13: 105–111.
32.
SiegelCHSammaritanoLR. Systemic lupus erythematosus: a review. JAMA2024; 331: 1480–1491.
33.
Rubio-RivasMHomsNACuarteroD, et al.The prevalence and incidence rate of pulmonary arterial hypertension in systemic sclerosis: systematic review and meta-analysis. Autoimmun Rev2021; 20: 102713.
34.
ClowseMEBJamisonMMyersE, et al.A national study of the complications of lupus in pregnancy. Am J Obstet Gynecol2008; 199: 127.e1-6.
35.
BlagojevicJAlOdhaibiKAAlyAM, et al.Pregnancy in systemic sclerosis: results of a systematic review and metaanalysis. J Rheumatol2020; 47: 881–887.
United Nations Inter-agency Group for Child Mortality Estimation, United Nations Children’s Fund, World Health Organization, World Bank, United Nations. Mortality Rate, Noenatal. World Bank Open Data, https://data.worldbank.org (accessed 10 September 2025).
38.
BonanniGAiroldiCBerghellaV. Birthweights at term have increased globally: insights from a systematic review of 183 million births. Am J Obstet Gynecol2024; 231: 395–407.e4.
39.
LiuEZhouY. Prognosis in pregnant females with systemic lupus erythematosus. Arch Rheumatol2017; 32: 298–302.
40.
AbdwaniRAl ShaqsiLAl-ZakwaniI. Neonatal and obstetrical outcomes of pregnancies in systemic lupus erythematosus. Oman Med J2018; 33: 15–21.
41.
IsmailFAbdel-AzeemMIEl-HaleemHA, et al.Feto-maternal outcome in patients with systemic sclerosis. Egypt Rheumatol2013; 35: 101–106.
42.
LuismanTSmithTRitchieS, et al.Genetic epidemiology approach to estimating birth incidence and current disease prevalence for rhizomelic chondrodysplasia punctata. Orphanet J Rare Dis2021; 16: 00.
WeinrebSJOkunowoOGriffisH, et al.Incidence of morbidity and mortality in a cohort of congenital complete heart block patients followed over 40 years. Heart Rhythm2022; 19: 1149–1155.
45.
JungJRahmanMRahmanM, et al.Effects of hemoglobin levels during pregnancy on adverse maternal and infant outcomes: a systematic review and meta-analysis. Ann N Y Acad Sci2019; 1450: 69–82.
46.
ShiHChenLWangY, et al.Severity of anemia during pregnancy and adverse maternal and fetal outcomes. JAMA Netw Open2022; 5: e2147046.
47.
American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 776: immune modulating therapies in pregnancy and lactation. Obstet Gynecol2019; 133: e287–e295.
48.
RüeggLPlumaAHamrounS, et al.EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update. Ann Rheum Dis2025; 84: 910–926.
49.
RussellMDDeyMFlintJ, et al.British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids. Rheumatology2023; 62: e48–e88.
50.
SalehZFSomersECRomeroVC, et al.Hydroxychloroquine in systemic lupus erythematosus, anti-SSA/SSB, and antiphospholipid antibody-positive pregnancies. Am J Obstet Gynecol2026; 234: 7–20.
51.
JølvingLRAnruPLNielsenJ, et al.The risk of chronic diseases and congenital malformations during childhood and adolescence after in utero exposure to thiopurines. Aliment Pharmacol Ther2021; 54: 1061–1069.
52.
ClearyBJKällénB. Early pregnancy azathioprine use and pregnancy outcomes. Birt Defects Res A Clin Mol Teratol2009; 85: 647–654.
53.
ColbensonGARoseCHErnsteFC, et al.Successful pregnancy outcome with connective tissue disease-associated interstitial lung disease: a case series. JCR J Clin Rheumatol2022; 28: e305–e307.
54.
NayakSSAdigaPKRaiL, et al.Severe rhizomelic chondrodysplasia punctata in a fetus due to maternal mixed connective tissue disorder. Genet Couns Geneva Switz2012; 23: 487–491.
55.
Park-WyllieLMazzottaPPastuszakA, et al.Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology2000; 62: 385–392.
56.
CarmichaelSLShawGMMaC, et al.Maternal corticosteroid use and orofacial clefts. Am J Obstet Gynecol2007; 197: 585.e1-7; discussion 683–684, e1-7.
57.
CaiECzuzoj-ShulmanNAbenhaimHA. Maternal and fetal outcomes in pregnancies with long-term corticosteroid use. J Matern-Fetal Neonatal Med Off J Eur Assoc Perinat Med Fed Asia Ocean Perinat Soc Int Soc Perinat Obstet2021; 34: 1797–1804.
58.
TodorokiYSatohMKuboS, et al.Anti-survival motor neuron complex antibodies as a novel biomarker for pulmonary arterial hypertension and interstitial lung disease in mixed connective tissue disease. Rheumatol Oxf Engl2024; 63: 1068–1075.
59.
ChaigneBChevalierKBouclyA, et al.In-depth characterization of pulmonary arterial hypertension in mixed connective tissue disease: a French National Multicentre Study. Rheumatol Oxf Engl2023; 62: 3261–3267.
60.
ThoreauBRenaudAChafeyP, et al.Anti-fibroblast and anti-endothelial cell autoantibodies in pulmonary arterial hypertension (PAH) in patients with connective tissue diseases (CTD). Rheumatol Oxf Engl2025; 64: 4041–4050.
61.
VeghJSzodorayPKappelmayerJ, et al.Clinical and immunoserological characteristics of mixed connective tissue disease associated with pulmonary arterial hypertension. Scand J Immunol2006; 64: 69–76.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
